Sun Pharmaceutical Industries Ltd.Strong Growth & Specialty Focus

Sun Pharmaceutical Industries delivered robust Q4 FY26 performance with revenues of ₹1,45,598 million, marking 13.6% year-over-year growth, while full-year FY26 revenues reached ₹582 billion, up 11.9%.

The company achieved a historic milestone as US Innovative Medicines crossed $1 billion annually for the first time, now surpassing the generics business in America. Global Innovative Medicines surged 20.1% to $354 million in Q4, representing 22.2% of total sales. India operations demonstrated exceptional momentum with 14.8% revenue growth and market share expansion from 8.1% to 8.4%, the highest gain since the Ranbaxy acquisition.

Management guided for high single-digit consolidated revenue growth in FY27 with R&D spend at 6-7% of sales. However, Q4 EBITDA margin compressed to 27.1% from 31.9% in Q3 due to elevated launch investments for UNLOXCYT and LEQSELVI, which will persist as base spending. The Organon acquisition remains on track for Q4 FY27 closure, promising further portfolio expansion. Net profit stood at ₹27,507 million with EPS of ₹11.31.